These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23374028)

  • 21. Macrolides in cystic fibrosis.
    McArdle JR; Talwalkar JS
    Clin Chest Med; 2007 Jun; 28(2):347-60. PubMed ID: 17467553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Azithromycin therapy in cystic fibrosis].
    Máiz Carro L; Cantón Moreno R
    Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.
    Torphy TJ; Allen J; Cantin AM; Konstan MW; Accurso FJ; Joseloff E; Ratjen FA; Chmiel JF;
    Ann Am Thorac Soc; 2015 Sep; 12(9):1398-406. PubMed ID: 26146892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.
    Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T; ; Amaral MD; de Boeck K; Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T
    J Cyst Fibros; 2019 Sep; 18(5):677-684. PubMed ID: 31303382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
    Tay GT; Reid DW; Bell SC
    Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State of progress in treating cystic fibrosis respiratory disease.
    Flume PA; Van Devanter DR
    BMC Med; 2012 Aug; 10():88. PubMed ID: 22883684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug development for cystic fibrosis.
    Sanders DB; Chmiel JF
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S10-S22. PubMed ID: 32940969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to therapies in cystic fibrosis: a targeted literature review.
    Narayanan S; Mainz JG; Gala S; Tabori H; Grossoehme D
    Expert Rev Respir Med; 2017 Feb; 11(2):129-145. PubMed ID: 28107795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.
    Gillan JL; Davidson DJ; Gray RD
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting airway inflammation in cystic fibrosis.
    McElvaney OJ; Wade P; Murphy M; Reeves EP; McElvaney NG
    Expert Rev Respir Med; 2019 Nov; 13(11):1041-1055. PubMed ID: 31530195
    [No Abstract]   [Full Text] [Related]  

  • 33. Emerging pharmacotherapies in cystic fibrosis.
    McElvaney OJ; Gunaratnam C; McElvaney OF; Bagwe I; Reeves EP; McElvaney NG
    Expert Rev Respir Med; 2018 Oct; 12(10):843-855. PubMed ID: 30129380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.
    Cogen JD; Nichols DP; Goss CH; Somayaji R
    J Pediatric Infect Dis Soc; 2022 Sep; 11(Supplement_2):S32-S39. PubMed ID: 36069901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?
    Klinger-Strobel M; Lautenschläger C; Fischer D; Mainz JG; Bruns T; Tuchscherr L; Pletz MW; Makarewicz O
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1351-74. PubMed ID: 25642831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
    Caverly LJ; Zhao J; LiPuma JJ
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
    Moore PJ; Tarran R
    Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapies for cystic fibrosis lung disease.
    Grasemann H; Ratjen F
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):653-9. PubMed ID: 20812885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drug treatments for cystic fibrosis.
    Zeitlin PL
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):523-35. PubMed ID: 14662004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.